Curanex Pharmaceuticals Inc (CURX)

Curanex Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.2	0.15	0.07	0
Cash & Short-Term Investments	0.2	0.15	0.07	0
Cash Growth	167.52%	100.21%	2960.33%	-
Other Receivables	-	-	-	0
Receivables	-	-	-	0
Inventory	-	-	-	0
Prepaid Expenses	0.01	0	-	-
Other Current Assets	0.49	0.37	-	0
Total Current Assets	0.7	0.52	0.07	0.01
Total Assets	0.79	0.52	0.07	0.01
Accounts Payable	0.13	0.01	-	-
Accrued Expenses	0	0.01	0.01	-
Total Current Liabilities	0.19	0.01	0.01	-
Total Liabilities	0.42	0.01	0.01	-
Common Stock	0	0	0	0
Additional Paid-In Capital	0.92	0.92	0.12	0.05
Retained Earnings	-0.76	-0.62	-0.26	-0.24
Comprehensive Income & Other	0.2	0.2	0.2	0.2
Total Common Equity	0.37	0.5	0.06	0.01
Shareholders' Equity	0.37	0.5	0.06	0.01
Total Liabilities & Equity	0.79	0.52	0.07	0.01
Net Cash (Debt)	-0.09	0.15	0.07	0
Net Cash Growth	-	100.21%	2960.33%	-
Net Cash Per Share	-0.00	0.01	0.12	0.00
Filing Date Shares Outstanding	27.75	24	0.6	0.6
Total Common Shares Outstanding	24	24	0.6	0.6
Working Capital	0.5	0.5	0.06	0.01
Book Value Per Share	0.02	0.02	0.10	0.02
Tangible Book Value	0.37	0.5	0.06	0.01
Tangible Book Value Per Share	0.02	0.02	0.10	0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q